Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479807 | 0.87 | SIRT2 (0.54) | FABP4KDM4CALDH1A1PTGS1PTGS2 | |
| SCHEMBL2021338 | 0.86 | KDM4C (0.70) | FABP4KDM4CPTGS1PTGS2KDM4D | |
| SCHEMBL15635769 | 0.85 | LMNA (0.55) | KDM4CPTGS1PTGS2MAPTDHODH | |
| SCHEMBL23547199 | 0.85 | MAPK13 (0.50) | FABP4KDM4CALDH1A1PTGS1PTGS2 | |
| SCHEMBL4905987 | 0.84 | AKR1C3 (0.59) | PTGS1PTGS2GFERAKR1C3AKR1C2 | |
| SCHEMBL10186488 | 0.81 | FABP4 (0.71) | FABP4KDM4CALDH1A1PTGS1PTGS2 | |
| Triflocin SCHEMBL3088829 | 0.80 | MPO (0.65) | ALDH1A1PTGS1PTGS2MAPK8AURKA | |
| SCHEMBL28741286 | 0.80 | FABP4 (0.65) | FABP4KDM4CALDH1A1PTGS1PTGS2 | |
| SCHEMBL3823398 | 0.78 | KDM4C (0.76) | KDM4CALDH1A1MAPTKDM4DKDM6B | |
| SCHEMBL19611328 | 0.78 | KDM4C (0.55) | KDM4CALDH1A1MAPTKDM4DKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5248781-A | Preparation of substituted anilino-nicotinic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | claimed |
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2411367-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| US-5248781-A | Preparation of substituted anilino-nicotinic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5248781-A | Preparation of substituted anilino-nicotinic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5248781-A | Preparation of substituted anilino-nicotinic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | FABP4 3997/4885KDM4C 2588/4885ALDH1A1 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.